Open access
Jul 2026
Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study
Six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus, and findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices.
R. García-Pérez, V. Siles-Guerrero, Aida Elhadri-Egea et al.
· Endocrines · 0 citations